TheStreet upgraded shares of PRA Health Sciences Inc. (NASDAQ:PRAH) from a hold rating to a buy rating in a research note published on Monday.

PRAH has been the topic of a number of other reports. Zacks Investment Research upgraded shares of PRA Health Sciences from a hold rating to a strong-buy rating and set a $65.00 target price on the stock in a report on Wednesday, October 5th. Citigroup Inc. boosted their target price on shares of PRA Health Sciences from $55.00 to $66.00 and gave the stock a buy rating in a report on Thursday, September 22nd. Credit Suisse Group AG restated a hold rating and issued a $50.00 target price on shares of PRA Health Sciences in a report on Thursday, November 3rd. Jefferies Group restated a buy rating on shares of PRA Health Sciences in a report on Tuesday, September 13th. Finally, KeyCorp restated a buy rating on shares of PRA Health Sciences in a report on Friday, November 4th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $55.86.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Shares of PRA Health Sciences (NASDAQ:PRAH) opened at 54.49 on Monday. The firm has a 50-day moving average of $55.24 and a 200 day moving average of $49.31. PRA Health Sciences has a one year low of $35.60 and a one year high of $60.96. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of 42.31 and a beta of 0.61.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, November 2nd. The company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. PRA Health Sciences had a net margin of 4.86% and a return on equity of 21.25%. The firm had revenue of $399.80 million for the quarter, compared to the consensus estimate of $394.87 million. During the same period in the previous year, the firm posted $0.52 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. On average, equities research analysts predict that PRA Health Sciences will post $2.47 EPS for the current year.

In other PRA Health Sciences news, CEO Colin Shannon sold 113,133 shares of the business’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $51.57, for a total value of $5,834,268.81. Following the completion of the sale, the chief executive officer now directly owns 120,000 shares of the company’s stock, valued at approximately $6,188,400. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.50% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in PRA Health Sciences by 26.0% in the second quarter. BlackRock Inc. now owns 2,399 shares of the company’s stock valued at $100,000 after buying an additional 495 shares during the period. Acrospire Investment Management LLC boosted its stake in PRA Health Sciences by 8.7% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the company’s stock valued at $104,000 after buying an additional 200 shares during the period. US Bancorp DE bought a new stake in PRA Health Sciences during the third quarter valued at about $106,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in PRA Health Sciences by 7.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,025 shares of the company’s stock valued at $114,000 after buying an additional 133 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its stake in PRA Health Sciences by 120.5% in the third quarter. BNP Paribas Arbitrage SA now owns 2,093 shares of the company’s stock valued at $118,000 after buying an additional 1,144 shares during the period.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.